Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Merck has received approval from the Food and Drug Administration for Welireg, its oral inhibitor for patients with certain rare types of neuroendocrine tumors. The company said Wednesday the ...

Gain insights, see trends and get real-time updates when you securely link or manually add your brokerage accounts.